PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Treatment with P. glandulosa (100mg/kg/day) in rat models showed efficacy as an antidiabetic agent [PMID:21645608]
Demonstrated cardioprotective and anti-hypertensive effects in rat models of pre-diabetes [PMID:23612947]
Prosopilosidine (PPD) showed potent in vivo activity against C. neoformans in a murine model, eliminating ~76% of organisms at 0.0625 mg/kg [PMID:29996473]
Chronic oral treatment (100 mg/kg/day) in rats blunted neutrophil infiltration and enhanced muscle repair after contusion injury [PMID:25625816]
Safety & adverse effects
Pregnancy & lactation
Evidence summary
PubMed sources
- 1.PMID: 24507365 (2014) — Macromolecular and functional properties of galactomannan from mesquite seed (Prosopis glandulosa). · Carbohydrate polymers
- 2.PMID: 35932513 (2022) — Reproductive disruption in adult female and male rats prenatally exposed to mesquite pod extract or daidzein. · Reproductive biology
- 3.PMID: 29996473 (2018) — Efficacy of Prosopilosidine from Prosopis glandulosa var. glandulosa against Cryptococcus neoformans Infection in a Murine Model. · Molecules (Basel, Switzerland)
- 4.PMID: 38273449 (2024) — Quantifying shrub-shrub competition in drylands using aerial imagery and a novel landscape competition index. · The New phytologist
- 5.PMID: 22366692 (2012)